7 Results for "

Atezolizumab

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Atezolizumab" in MCE Product Catalog:

42
42 Cited Publications
Cat. No.: HY-P9904
CAS No.: 1380723-44-3
Synonyms: MPDL3280A; RG-7446; RO-5541267

Research Areas:  

Cancer

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
loading...
    loading...
Cat. No.: HY-P9986
CAS No.: 1918185-84-8
Synonyms: MTIG-7192A; RG-6058

Target:  

CD28

Research Areas:  

Cancer

Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .
loading...
    loading...
Cat. No.: HY-174304
Research Areas:  

Cancer

Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide is a drug-linker conjugates for ADC. Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide consists of Triptolide (HY-32735) and a stable cleavable linker (Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-Cl) (HY-174810). Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide can be used for the synthesis of antibody-drug conjugates (ADCs) .
loading...
    loading...
Cat. No.: HY-P99249
CAS No.: 1638935-72-4
Synonyms: Pogalizumab; MOXR 0916

Research Areas:  

Cancer

Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
loading...
    loading...
Cat. No.: HY-171572
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
loading...
    loading...
Cat. No.: HY-P991186

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model .
loading...
    loading...
Cat. No.: HY-181916
BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma .
loading...
    loading...